Európska únia - slovenčina - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcie syncytiálneho vírusu dýchacích ciest - vakcíny - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. pozri časti 4. 2 a 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

bracco imaging deutschland gmbh, nemecko - jomeprol - 48 - diagnostica

Európska únia - slovenčina - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedémy, dedičné - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Európska únia - slovenčina - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - lieky na liečbu chorôb kostí - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.